(Reuters) – Johnson & Johnson said on Tuesday it would delay the rollout of its COVID-19 vaccine in Europe and was reviewing cases of extremely rare blood clots in people after they received the shot with European health authorities.
U.S. federal health agencies on Tuesday recommended pausing the use of the COVID-19 vaccine as six women under 50 developed rare blood clots after receiving the shot, dealing a fresh setback to efforts to tackle the pandemic. (https://bit.ly/3tf2s85)
(Reporting by Ankur Banerjee in Bengaluru; Editing by Shinjini Ganguli)
